News & Updates

An intensive targeting of low-density lipoprotein cholesterol (LDL-C) level (<55 mg/dL) reduces the risk of cardiovascular events at 3 years in patients with atherosclerotic cardiovascular disease (ASCVD) when compared with conventional targeting (<70 mg/dL), results of the Ez-PAVE trial have shown.

Use of semaglutide and, to a lesser extent, liraglutide is associated with significantly lower risk of worsening mental illness in patients with depression or anxiety vs non-use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a national cohort study has found.